---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-120668"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:31:26.326238+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BiomX subsidiary BiomX Ltd files for insolvency; Phase 2b study discontinued

## Summary
- Phase 2b study discontinued Dec 8 due to resource constraints exceeding available funds.
- Dec 11: Board of BiomX Ltd authorized filing for insolvency proceedings in Israel.
- Company evaluating strategic options; continues BX011 program via Adaptive Phage Therapeutics.
- Limited financial resources cited as primary reason for study discontinuation and insolvency filing.

## SEC filing metadata
- accession: 0001213900-25-120668
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390025120668/0001213900-25-120668-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390025120668/ea0269336-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-120668
- JSON: https://secwatch.observer/filing/0001213900-25-120668.json
- Plain text: https://secwatch.observer/filing/0001213900-25-120668.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.